3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Advanced Solid Tumor
6
Solid Tumors
3
Solid Tumor
3
Mesothelioma
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor, Adult
2
Melanoma
2
Cholangiocarcinoma
2
Advanced Solid Tumors
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Refractory or Recurrent Solid Tumor
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Locally Advanced or Metastatic Solid Tumors
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
DMMR Colorectal Cancer
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Refractory or Recurrent Solid Tumor
×
spartalizumab
×
Other solid neoplasm
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled